Valuation: Moderna, Inc.

Market Cap 25.73B 133B 22.22B 20.84B 18.98B 35.7B 2,461B 36.19B 244B 95.75B 1,233B 96.62B 94.53B 4,101B P/E 2026 *
-7.51x
P/E 2027 * -13.1x
Enterprise Value 22.09B 114B 19.07B 17.89B 16.29B 30.63B 2,112B 31.06B 210B 82.17B 1,058B 82.92B 81.12B 3,519B EV / Sales 2026 *
10.5x
EV / Sales 2027 * 9.66x
Free-Float
92.68%
Yield 2026 *
-
Yield 2027 * -
1 day+3.85%
1 week+14.26%
Current month+21.44%
1 month+5.86%
3 months+35.92%
6 months+47.48%
Current year+103.23%
1 week 15.4
Extreme 15.4
17
1 month 13.36
Extreme 13.36
17
Current year 8.1
Extreme 8.1
22
1 year 6.02
Extreme 6.02
22
3 years 6.02
Extreme 6.02
44
5 years 6.02
Extreme 6.02
121.74
10 years 6.02
Extreme 6.02
130.62
Manager TitleAgeSince
Chief Executive Officer 54 2011-02-28
Director of Finance/CFO 49 2022-09-05
President 50 2024-10-31
Director TitleAgeSince
Chairman 63 2012-01-31
Director/Board Member 54 2011-02-28
Director/Board Member 69 2019-12-10
Change 5-day change 1-year change 3-year change Capi.($)
+3.85%+14.26% - - 25.28B
+0.30%-0.26%+38.86%+1.15% 80.23B
-1.02%-1.34%-2.54%+30.42% 50.64B
+1.46%-4.31%+11.90%+164.55% 46.87B
+16.63%+13.18%-42.30%-42.14% 46.34B
-0.32%+0.98%+50.90%-20.02% 31B
+1.80%+7.77%+130.05%-39.33% 25.28B
+2.78%+1.60%+42.08%+92.34% 24.36B
-0.16%-0.58%-6.77%+202.07% 20.81B
+3.95%+1.64%+67.20%+120.52% 16.08B
Average +2.88%+0.42%+32.15%+56.62% 37.96B
Weighted average by Cap. +2.87%+0.17%+24.64%+41.48%

Financials

2026 *2027 *
Net sales 2.11B 10.92B 1.82B 1.71B 1.55B 2.92B 201B 2.96B 20B 7.84B 101B 7.91B 7.74B 336B 2.43B 12.59B 2.1B 1.97B 1.79B 3.37B 232B 3.42B 23.06B 9.03B 116B 9.12B 8.92B 387B
Net income -3.38B -17.51B -2.92B -2.74B -2.49B -4.69B -323B -4.75B -32.08B -12.57B -162B -12.69B -12.41B -538B -1.92B -9.97B -1.66B -1.56B -1.42B -2.67B -184B -2.71B -18.27B -7.16B -92.16B -7.22B -7.07B -307B
Net Debt -3.65B -18.91B -3.15B -2.96B -2.69B -5.06B -349B -5.13B -34.65B -13.58B -175B -13.7B -13.4B -581B -2.27B -11.77B -1.96B -1.84B -1.68B -3.15B -217B -3.19B -21.57B -8.45B -109B -8.53B -8.34B -362B
Logo Moderna, Inc.
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (96.1%); - revenue from collaboration agreements (1.5%); - revenue from royalties and licensing (1.3%); - revenue from grants (1.1%). At the end of 2024, the group's portfolio comprises 37 products in clinical development, of which 10 in phase I, 18 in phase II and 9 in phase III, 3 products in preclinical development, and 4 products in commercial phase. Net sales are distributed geographically as follows: the United States (55.1%), Europe (18.5%) and other (26.4%).
Employees
4,700
Date Price Change Volume
26-08-17 R$16.99 +5.40% 7,869
26-08-14 R$16.12 -3.36% 6,743
26-08-13 R$16.68 +1.96% 43,159
26-08-12 R$16.36 +5.55% 23,245
26-08-11 R$15.50 +4.24% 8,168
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
23
Last Close Price
64.46USD
Average target price
50.84USD
Spread / Average Target
-21.13%

Quarterly revenue - Rate of surprise